Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Seattle Genetics Inc (SGEN)

Seattle Genetics Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,666,544
  • Shares Outstanding, K 171,386
  • Annual Sales, $ 654,700 K
  • Annual Income, $ -222,690 K
  • 60-Month Beta 2.00
  • Price/Sales 29.66
  • Price/Cash Flow N/A
  • Price/Book 10.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.49
  • Number of Estimates 9
  • High Estimate -0.43
  • Low Estimate -0.58
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +14.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.54 +39.02%
on 10/16/19
114.81 -0.05%
on 11/15/19
+31.37 (+37.62%)
since 10/15/19
3-Month
65.44 +75.35%
on 09/10/19
114.81 -0.05%
on 11/15/19
+38.04 (+49.59%)
since 08/15/19
52-Week
51.50 +122.82%
on 12/24/18
114.81 -0.05%
on 11/15/19
+60.36 (+110.98%)
since 11/15/18

Most Recent Stories

More News
Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it has submitted an arbitration demand to the American Arbitration Association to resolve its dispute with Daiichi Sankyo Co. Ltd. regarding the...

SGEN : 114.75 (+1.29%)
Look for Shares of Seattle Genetics to Potentially Pullback after Yesterday's 32.61% Rise

Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $107.68 to a high of $109.30. Yesterday, the shares gained 32.6%, which took the trading range above the 3-day high...

SGEN : 114.75 (+1.29%)
Seattle Genetics Announces Multiple ADCETRIS(R) (Brentuximab Vedotin) Presentations at the ASH Annual Meeting

---Additional Data Analyses Highlight Activities Across Broad ADCETRIS Development Program-

SGEN : 114.75 (+1.29%)
Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate

Seattle Genetics, Inc. (Nasdaq: SGEN) and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160) today announced that the companies have entered into a license agreement for an advanced preclinical product candidate...

BGNE : 198.25 (+0.94%)
SGEN : 114.75 (+1.29%)
Seattle Genetics Responds to Daiichi Sankyo's Complaint for Declaratory Judgment

Seattle Genetics, Inc. (Nasdaq:SGEN) today released the following statement in response to Daiichi Sankyo's filing of a Declaratory Judgment action alleging Seattle Genetics is not entitled to intellectual...

SGEN : 114.75 (+1.29%)
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology

Daiichi Sankyo Co., Ltd announced today that the company has filed a Declaratory Judgement action in the District Court of Delaware in response to receiving communications from Seattle Genetics, Inc. with...

DSNKY : 61.5000 (-0.11%)
SGEN : 114.75 (+1.29%)
Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 10:20 a.m. Mountain Time. The presentation...

SGEN : 114.75 (+1.29%)
Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark

Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.

RHHBY : 37.5300 (+0.51%)
MRK : 84.90 (+0.41%)
SGEN : 114.75 (+1.29%)
TAK : 20.37 (+1.80%)
Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -45.95% and 1.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

SGEN : 114.75 (+1.29%)
Seattle Genetics: 3Q Earnings Snapshot

BOTHELL, Wash. (AP) _ Seattle Genetics Inc. (SGEN) on Tuesday reported a loss of $91.9 million in its third quarter.

SGEN : 114.75 (+1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade SGEN with:

Business Summary

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability...

See More

Key Turning Points

2nd Resistance Point 115.96
1st Resistance Point 115.36
Last Price 114.75
1st Support Level 113.60
2nd Support Level 112.44

See More

52-Week High 114.81
Last Price 114.75
Fibonacci 61.8% 90.63
Fibonacci 50% 83.15
Fibonacci 38.2% 75.68
52-Week Low 51.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar